Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo.

Open Access
Publisher Website
Google Scholar
Abstract
Somatostatin analogs have become a focus of interest in clinical oncology, and promising results in patients with gastrointestinal tract cancers have been published in the recent literature (1) . While these data suggest a potential survival benefit with the application of somatostatin analogs in advanced pancreatic cancer, results have also been reported that indicate the absence of somatostatin receptors (SSTRs) in pancreatic adenocarcinomas (2) . In addition, Fisher et al. (3) ) have recently reported the detection of messenger RNAs (mRNAs) encoding SSTR1, SSTR2, and SSTR5 in pancreatic cancer cells, but the absence of functional somatostatin binding sites on the cell surface.